Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for renal angiomyolipoma size reduction
IRCT20201108049311N9Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in kidney angiomyolipoma (AML), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Change in angiomyolipoma tumor size, Tolerance and side effects of long-term sirolimus and 1 more. Started Oct 2024; status: completed.
02
Drugs
sirolimus
03
Conditions
kidney angiomyolipoma (AML)
Beyond the preview
Go deeper on IRCT20201108049311N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201108049311N9.